Can a patient who has received eight days of intravenous acyclovir and is clinically improved be safely discharged, or is a longer treatment course required?

Can This Patient Be Safely Discharged After 8 Days of IV Acyclovir?

No, this patient should not be discharged yet—the standard treatment duration for HSV encephalitis is 14-21 days of intravenous acyclovir, and 8 days falls short of this evidence-based minimum. 1

Why 8 Days Is Insufficient

The most authoritative guidelines are clear and consistent on this point:

• The IDSA (2008) recommends 14-21 days of IV acyclovir for herpes simplex encephalitis 2
• The British Neurologists/British Infection Association (2012) guidelines strongly recommend 14-21 days (Grade A, Level II evidence) 1

The original clinical trials used only 10 days of treatment, but documented relapses after this shorter course led to the current 14-21 day standard 1. One case report demonstrated relapse just 4 days after completing a 10-day course, with subsequent brain biopsy confirming active HSV-1 infection 3. This is why the treatment duration was extended.

What You Must Do Before Discharge

Perform a repeat lumbar puncture to confirm CSF HSV PCR is negative 1. This is a Grade B, Level II recommendation from the British guidelines.

The discharge algorithm is:

1. Complete at least 14 days of IV acyclovir (21 days is preferred for severe cases)
2. Obtain repeat CSF at 14-21 days
3. If CSF HSV PCR is still positive: Continue IV acyclovir with weekly PCR testing until negative 1
4. If CSF HSV PCR is negative: Can complete treatment course and discharge

Important caveats:

• A negative CSF PCR at the end of therapy correlates with better outcomes 2
• Oral acyclovir does NOT achieve adequate CSF levels and cannot substitute for IV therapy 1
• Valacyclovir (2g three times daily) may have a role for ongoing treatment if CSF remains positive after 2-3 weeks, but this is still being studied 1

Clinical Improvement Alone Is Not Sufficient

While clinical improvement is encouraging, it does not indicate viral clearance. The mortality benefit of acyclovir (reducing mortality from 70% to 20-30%) 1 and the risk of relapse with inadequate treatment duration make completing the full course critical for long-term morbidity and mortality outcomes.

Practical Considerations

If IV access or hospitalization is truly problematic after 14 days with negative CSF PCR, high-dose valacyclovir could theoretically be considered, though this is not standard practice and lacks robust evidence in adults 1. The safer approach is completing IV therapy as recommended.

Bottom line: Continue IV acyclovir to at least day 14, obtain repeat LP with HSV PCR, and base discharge on both clinical improvement AND negative CSF PCR.